Reported Earnings • May 31
Second quarter 2026 earnings released: CA$0.016 loss per share (vs CA$0.021 loss in 2Q 2025) Second quarter 2026 results: CA$0.016 loss per share (improved from CA$0.021 loss in 2Q 2025). Net loss: CA$528.3k (loss narrowed 22% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 04
First quarter 2026 earnings released: CA$0.018 loss per share (vs CA$0.018 loss in 1Q 2025) First quarter 2026 results: CA$0.018 loss per share (in line with 1Q 2025). Net loss: CA$595.8k (loss widened 1.4% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. Reported Earnings • Jan 29
Full year 2025 earnings released: CA$0.075 loss per share (vs CA$0.075 loss in FY 2024) Full year 2025 results: CA$0.075 loss per share (in line with FY 2024). Net loss: CA$2.51m (loss widened 13% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings. Board Change • Jun 04
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 5 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 22
Second quarter 2025 earnings released: CA$0.021 loss per share (vs CA$0.018 loss in 2Q 2024) Second quarter 2025 results: CA$0.021 loss per share (further deteriorated from CA$0.018 loss in 2Q 2024). Net loss: CA$679.8k (loss widened 37% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings. Reported Earnings • Mar 02
First quarter 2025 earnings released: CA$0.018 loss per share (vs CA$0.018 loss in 1Q 2024) First quarter 2025 results: CA$0.018 loss per share (in line with 1Q 2024). Net loss: CA$587.5k (loss widened 25% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Reported Earnings • Jan 30
Full year 2024 earnings released: CA$0.075 loss per share (vs CA$0.24 loss in FY 2023) Full year 2024 results: CA$0.075 loss per share (improved from CA$0.24 loss in FY 2023). Net loss: CA$2.23m (loss narrowed 65% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. New Risk • Sep 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Market cap is less than US$10m (CA$4.62m market cap, or US$3.40m). Minor Risk Shareholders have been diluted in the past year (21% increase in shares outstanding). Reported Earnings • Aug 30
Third quarter 2024 earnings released: CA$0.019 loss per share (vs CA$0.021 loss in 3Q 2023) Third quarter 2024 results: CA$0.019 loss per share. Revenue: CA$200.3k (up CA$200.1k from 3Q 2023). Net loss: CA$547.3k (loss widened 11% from 3Q 2023). Reported Earnings • Jun 04
Second quarter 2024 earnings released: CA$0.018 loss per share (vs CA$0.015 loss in 2Q 2023) Second quarter 2024 results: CA$0.018 loss per share (further deteriorated from CA$0.015 loss in 2Q 2023). Net loss: CA$495.1k (loss widened 47% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Reported Earnings • Mar 01
First quarter 2024 earnings released: CA$0.018 loss per share (vs CA$0.011 loss in 1Q 2023) First quarter 2024 results: CA$0.018 loss per share (further deteriorated from CA$0.011 loss in 1Q 2023). Net loss: CA$471.1k (loss widened 95% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. New Risk • Jan 30
New major risk - Revenue and earnings growth Earnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$7.9m). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (CA$1.0k revenue, or US$777). Market cap is less than US$10m (CA$6.92m market cap, or US$5.16m). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding). Reported Earnings • Jan 30
Full year 2023 earnings released: CA$0.24 loss per share (vs CA$0.068 loss in FY 2022) Full year 2023 results: CA$0.24 loss per share (further deteriorated from CA$0.068 loss in FY 2022). Net loss: CA$6.30m (loss widened 332% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings. Board Change • Jan 17
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Dec 28
Biosenta Inc. announced that it has received CAD 0.5 million in funding On December 27, 2023, Biosenta Inc. closed the transaction. The securities issued pursuant to the Offering will be subject to a four-month plus one day "hold period" expiring April 29, 2024, as prescribed by applicable Canadian securities laws. Board Change • Dec 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Dec 17
Biosenta Inc. announced that it expects to receive CAD 0.5 million in funding Biosenta Inc. announced a non-brokered private placement financing to issue 1,250,000 units at an issue price of CAD 0.40 per unit for the gross proceeds of CAD 500,000 on December 15, 2023. Each Unit will consist of one common share and one half of common share purchase warrant. Each Warrant will entitle the holder thereof to acquire, subject to adjustment in certain events, one common share at an exercise price of CAD 0.80 for a period of 18 months from the closing date of the Offering. The closing of the Offering is expected to occur on or about December 22, 2023, or such other date or dates as the Company may determine. The securities issued pursuant to the Offering shall be subject to a four-month plus one day hold period from the closing date in accordance with applicable Canadian securities laws. Board Change • Nov 24
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Aug 10
Biosenta Inc. Announces Further Advances in Research and Development of Tri-Filler Biosenta Inc. announced further advances in research and development of the Tri-Filler particle composed of Ca(OH)2 (calcium hydroxide) core with a CaCO3 (calcium carbonate) encapsulation. Ongoing development of new methods of production of Tri-Filler by Dr. Maen Husein of the Department of Chemical Engineering at the University of Calgary and his team have reduced aggregation and resulted in the production of Tri-Filler particles being more uniform in shape and morphology. Additionally, using these new production methods, Tri-Filler can now be produced continuously at a higher rate than previously achieved. The University of Calgary team continues to investigate the mechanism of encapsulation of calcium hydroxide with calcium carbonate with a view to improving Tri-Filler's performance in industrial applications and exploring Tri-Filler's ability to serve as an effective carbon sink. Preliminary testing conducted by SGS Canada Inc. using accelerated aging, indicates that Tri-Filler may have a shelf life of up to 99 years. Dr. Mehdi Mohammadi Ashani, a Postdoctoral Fellow in Microbiology and Bioengineering at the University of Calgary, continues to study Tri-Filler on its own and in combination with other materials, to assess its efficacy against a diverse range of microorganisms, encompassing gram-positive and gram-negative bacteria including S.aureus, P.aeruginosa, and E.coli as well as fungi, including C.albecan and C.auris. Lab testing of Tri-Filler as an anti-microbial has shown very promising results. By incorporating CO2 in the encapsulation process, Tri-Filler aids in reducing CO2 emissions, helping businesses in achieving their sustainability goals. Board Change • Aug 04
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Jul 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Shares are highly illiquid. Negative equity (-CA$3.5m). Revenue is less than US$1m (CA$1.3k revenue, or US$1.0k). Market cap is less than US$10m (CA$10.6m market cap, or US$7.99m). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (15% increase in shares outstanding). Annuncio • Jul 18
Biosenta Inc., Annual General Meeting, Aug 24, 2023 Biosenta Inc., Annual General Meeting, Aug 24, 2023. Reported Earnings • Jun 01
Second quarter 2023 earnings released Second quarter 2023 results: Net loss: CA$336.8k (loss narrowed 84% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 49% per year, which means it is well ahead of earnings. Board Change • May 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Apr 28
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Mar 07
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jan 29
Full year 2022 earnings released: CA$0.068 loss per share (vs CA$0.12 loss in FY 2021) Full year 2022 results: CA$0.068 loss per share (improved from CA$0.12 loss in FY 2021). Net loss: CA$1.46m (loss narrowed 29% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has increased by 62% per year, which means it is well ahead of earnings. Board Change • Nov 22
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jul 12
Biosenta Inc., Annual General Meeting, Aug 16, 2022 Biosenta Inc., Annual General Meeting, Aug 16, 2022. Board Change • Jul 05
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 29
Second quarter 2022 earnings released: CA$0.11 loss per share (vs CA$0.027 loss in 2Q 2021) Second quarter 2022 results: CA$0.11 loss per share (down from CA$0.027 loss in 2Q 2021). Net loss: CA$2.15m (loss widened 349% from 2Q 2021). Board Change • Apr 28
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 03
First quarter 2022 earnings: Revenues and EPS in line with analyst expectations First quarter 2022 results: CA$0.028 loss per share (down from CA$0.02 loss in 1Q 2021). Revenue: CA$292 (down 99% from 1Q 2021). Net loss: CA$548.3k (loss widened 59% from 1Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings. Board Change • Dec 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Nick Iacono was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions Derivative • Aug 29
President exercised options to buy CA$204k worth of stock. On the 23rd of August, Amarvir Gill exercised options to buy 385k shares at a strike price of around CA$0.20, costing a total of CA$77k. This transaction amounted to 28% of their direct individual holding at the time of the trade. Since September 2020, Amarvir's direct individual holding has increased from 1.37m shares to 1.38m. Company insiders have collectively sold CA$55k more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Jun 08
Independent Director recently sold CA$113k worth of stock On the 4th of June, Dene Rogers sold around 316k shares on-market at roughly CA$0.36 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$107k more than they bought in the last 12 months. Is New 90 Day High Low • Dec 17
New 90-day high: CA$0.75 The company is up 85% from its price of CA$0.41 on 17 September 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Household Products industry, which is up 1.0% over the same period. Is New 90 Day High Low • Dec 02
New 90-day low: CA$0.25 The company is down 34% from its price of CA$0.38 on 02 September 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Household Products industry, which is up 1.0% over the same period. Annuncio • Sep 26
Biosenta Inc. Announces Finalization of Four-Year Research Partnership with the University of Calgary Biosenta Inc. ('Biosenta' or the 'Company') announced the finalization of a four-year research partnership with the University of Calgary. Biosenta has wasted no time in creating innovation in Alberta. A research partnership with the University of Calgary Research Group and AMPAK Inc. from Toronto, Ontario, is official. This partnership enables the University team to undertake a new generation of research in the world of nanoparticles for use as an anti-microbial filler in commercial construction materials and plastic consumer products and goods packaging. The University of Calgary team has demonstrated expertise in this field, previously improving the tensile strength of concrete by 80%. The University of Calgary team has also improved the performance of drilling fluids and ceramic membranes using nanoparticle technology.
AMPAK Inc. is proud to be the first Industry research partner to commit to the project. The scope of AMPAK’s involvement includes plastic product development, research and development, and commercial consumer packaging. The partnership’s goal is to synthesize nanoscale core-shell particles and standardize the production process of Biosenta’s patented two-part, food-grade nanoparticles called Tri-filler. Tri-filler not only has attributes of being anti-microbial, but also strength enhancement and fire-retardant capabilities. This innovation has the potential to revolutionize the antiviral properties of everyday surfaces such as clothes, paint, drywall, concrete, common surfaces and consumer packaging materials. The project principal is actively looking to engage with businesses or commercial entities seeking to improve their products’ and materials’ anti-microbial properties. The impact on the community is measurable and two-fold. Firstly, there is an incredible opportunity for local organizations that currently use nanoparticles as fillers to get involved in development and testing activities as research partners. Secondly, the University team has dedicated a significant portion of their efforts to measuring nanoparticles’ impact on human health and their concentration levels within the body over time due to consistent exposure, even at minimal parts-per-million. The University team is implementing theories to safely integrate the nanoparticles within compounds to improve end-user safety and increase the filler’s usability in multiple consumer applications. 
